Communiqués Theralink Technologies, Inc.

Actions

THER

US88339Q1094

Marché Fermé - OTC Markets Autres places de cotation 20:55:22 13/06/2024			Varia. 5j.	Varia. 1 janv.
0,0001 ^USD	0,00%		0,00%	-93,33%

07/05	IMAC Holdings, Inc. (NasdaqCM:BACK) a acquis les actifs de Theralink Technologies, Inc.	CI
06/05	Theralink Technologies, Inc. (OTCPK:THER) a annulé l'acquisition d'IMAC Holdings, Inc. (NasdaqCM:BACK) dans le cadre d'une opération de fusion inversée.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Theralink Technologies : Accelaration/Increase of Financial Obligation - Form 8-K	06/03	PU
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates	18/12	AQ
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4	13/11	AQ
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board	03/11	AQ
Four Penny Stocks That Might Move On News (EPAZ, THER, SDNR, HNRC)	05/10/23	AQ
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023	04/10/23	AQ
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer	27/06/23	AQ
Theralink Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University	04/04/23	AQ
Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University	03/04/23	PR
Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone	23/02/23	PR
THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	21/02/23	AQ
THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	01/02/23	AQ
Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative	17/01/23	PR
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization	09/01/23	PR
THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	29/12/22	AQ
THERALINK TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	09/12/22	AQ
THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)	01/12/22	AQ
Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium	01/12/22	PR
Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares	29/11/22	PR
Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment	14/11/22	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Theralink Technologies, Inc.

Actions

THER

US88339Q1094

Communiqués

Filtres